Yousif Capital Management LLC Has $794,000 Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Yousif Capital Management LLC lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 1.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 17,839 shares of the company’s stock after selling 303 shares during the period. Yousif Capital Management LLC’s holdings in Omnicell were worth $794,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Curi RMB Capital LLC lifted its stake in shares of Omnicell by 0.7% in the 3rd quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock worth $3,872,000 after purchasing an additional 651 shares during the period. KBC Group NV raised its holdings in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after acquiring an additional 778 shares in the last quarter. 1620 Investment Advisors Inc. increased its position in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Omnicell by 7.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock worth $1,102,000 after buying an additional 1,813 shares during the last quarter. Finally, Creative Planning raised its holdings in Omnicell by 23.1% during the 3rd quarter. Creative Planning now owns 11,667 shares of the company’s stock valued at $509,000 after buying an additional 2,188 shares during the period. 97.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on OMCL shares. Benchmark reissued a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co. raised their price objective on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Craig Hallum lifted their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Bank of America reduced their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Finally, Wells Fargo & Company cut their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $52.33.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $39.61 on Friday. The firm has a market capitalization of $1.83 billion, a P/E ratio of 146.71, a P/E/G ratio of 26.98 and a beta of 0.78. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74. The company’s fifty day moving average price is $43.64 and its 200 day moving average price is $43.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 0.95.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, sell-side analysts predict that Omnicell, Inc. will post 1.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.64% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.